Regulus Publishes Data Showing miR-33 Antagonism Impacts Atherosclerosis
June 09, 2011
Regulus Publishes Data Showing miR-33 Antagonism Impacts Atherosclerosis
Mice treated with a miR-33 antagonist displayed increased HDL-C, enhanced reverse cholesterol transport to the plasma, liver, and feces, and reductions in plaque size and lipid content.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tools & Techniques: siRNA Delivery to Endothelia; miRNA Analysis in Non-Model Animals; and More
May 9, 2013 / Gene Silencing News - People in the News: William Rastetter, Carlo Croce, Tyler Jacks, Phillip Sharp
April 4, 2013 / Gene Silencing News - In Print: Last Month's RNAi- and microRNA-Related Papers of Note
February 14, 2013 / Gene Silencing News - In Print: Last Month's RNAi- and microRNA-Related Papers of Note
January 17, 2013 / Gene Silencing News - UNC Researchers Report New Details on Role of miR-122 in HCV
December 20, 2012 / Gene Silencing News